Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV

被引:10
作者
Zou, Shi [1 ,2 ]
Guo, Wei [3 ,4 ]
Wu, Songjie [2 ,5 ]
Ming, Fangzhao [6 ]
Tan, Yuting [1 ,2 ]
Wu, Mengmeng [1 ,2 ]
Tang, Weiming [7 ,8 ]
Liang, Ke [1 ,2 ,5 ,9 ]
机构
[1] Wuhan Univ, Dept Infect Dis, Zhongnan Hosp, Wuhan, Peoples R China
[2] Chinese Acad Med Sci, Wuhan Res Ctr Infect Dis & Canc, Wuhan, Peoples R China
[3] Wuhan Univ, Dept Pathol, Zhongnan Hosp, Wuhan, Peoples R China
[4] Wuhan Univ, Sch Basic Med Sci, Dept Pathol, Wuhan, Peoples R China
[5] Wuhan Univ, Dept Nosocomial Infect Management, Zhongnan Hosp, Wuhan, Peoples R China
[6] Wuchang Dist Ctr Dis Control & Prevent, Wuhan, Peoples R China
[7] Guangdong 2 Prov Peoples Hosp, Guangzhou, Peoples R China
[8] Univ North Carolina Chapel Hill Project China, Guangzhou, Peoples R China
[9] Hubei Engn Ctr Infect Dis Prevent Control & Treatm, Wuhan, Peoples R China
关键词
neutralizing antibodies; inactivated COVID-19 vaccine; people living with HIV (PLWH); seroconversion; longitudinal humoral response; DISEASE; 2019; COVID-19; SARS-COV-2; SAFETY; IMMUNOGENICITY; COHORT;
D O I
10.3389/fimmu.2022.988304
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Longitudinal humoral immune response to inactivated COVID-19 vaccines among people living with HIV (PLWH) have not yet been systematically investigated. We conducted a 6-month longitudinal study among vaccinated PLWH and HIV-Negative Controls (HNC) to determine whether the humoral immune response effects of the inactivated COVID-19 vaccine are different between the two groups of people. Totally, 46 PLWH and 38 HNC who received the inactivated COVID-19 vaccine on days 0 and 28 were enrolled. The SARS-CoV-2 neutralizing antibodies (nAbs) and total specific IgM and IgG antibodies were examined on Day 0-Day190. The level and positive seroconversion rate of nAbs peaked on Day 42 in HNC while peaked on Day 70 in PLWH, then decreased gradually with the extension of the vaccination period after the peaks. The peak level of nAbs in PLWH on Day 70, (GMC 8.07 BAU/mL, 95% CI 5.67-11.48) was significantly lower than in HNC on Day 42 (GMC 18.28 BAU/mL, 95% CI 10.33-32.33, P =0.03). The decrease in the geometric mean concentrations (GMCs) of nAbs was observed as 42.9% in PLWH after peak level, which decreased from 8.07 BAU/mL [95% CI: 5.67-11.48] on Day 70 to 4.61 BAU/mL [95% CI: 3.35-6.34] on Day 190 (p = 0.02). On Day 190, only seven (18%, [95% CI: 6-40]) HNC and five (11%, [95% CI: 4-25]) PLWH maintained positive nAbs response respectively. The geometric mean ELISA units (GMEUs) and positive seroconversion rate of IgG in PLWH dropped significantly from Day 70 (GMEUs, 0.20 EU/mL, [95% CI: 0.13-0.34]; seroconversion, 52%, [95% CI: 34-69]) to Day 190 (GMEUs, 0.05 EU/mL, [95% CI: 0.03-0.08], P<0.001; seroconversion, 18%, [95% CI: 8-33], P<0.001). There was no significant difference in levels and seroconversion rates of nAbs and IgG between the two groups on Day 190. The peak immunogenicity of the inactivated COVID-19 vaccine was delayed and inferior in PLWH compared to HNC, while no significant difference was found in six-month immunogenicity between the two groups.
引用
收藏
页数:7
相关论文
共 24 条
[1]   What do we know about the antibody responses to SARS-CoV-2? [J].
Alejandro Lagunas-Rangel, Francisco ;
Chavez-Valencia, Venice .
IMMUNOBIOLOGY, 2021, 226 (02)
[2]   Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV [J].
Ao, Ling ;
Lu, Ting ;
Cao, Yu ;
Chen, Zhiwei ;
Wang, Yuting ;
Li, Zisheng ;
Ren, Xingqian ;
Xu, Pan ;
Peng, Mingli ;
Chen, Min ;
Zhang, Gaoli ;
Xiang, Dejuan ;
Cai, Dachuan ;
Hu, Peng ;
Shi, Xiaofeng ;
Zhang, Dazhi ;
Ren, Hong .
EMERGING MICROBES & INFECTIONS, 2022, 11 (01) :1126-1134
[3]   Severe Covid-19 [J].
Berlin, David A. ;
Gulick, Roy M. ;
Martinez, Fernando J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2451-2460
[4]   SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review [J].
Fathizadeh, Hadis ;
Afshar, Saman ;
Masoudi, Mahmood Reza ;
Gholizadeh, Pourya ;
Asgharzadeh, Mohammad ;
Ganbarov, Khudaverdi ;
Kose, Sukran ;
Yousefi, Mehdi ;
Kafil, Hossein Samadi .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2021, 188 :740-750
[5]   Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study [J].
Feng, Yanmeng ;
Zhang, Yifan ;
He, Zhangyufan ;
Huang, Haojie ;
Tian, Xiangxiang ;
Wang, Gang ;
Chen, Daihong ;
Ren, Yanqin ;
Jia, Liqiu ;
Wang, Wanhai ;
Wu, Jing ;
Shao, Lingyun ;
Zhang, Wenhong ;
Tang, Heng ;
Wan, Yanmin .
ECLINICALMEDICINE, 2022, 43
[6]   Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial [J].
Frater, John ;
Ewer, Katie J. ;
Ogbe, Ane ;
Pace, Mathew ;
Adele, Sandra ;
Adland, Emily ;
Alagaratnam, Jasmini ;
Aley, Parvinder K. ;
Ali, Mohammad ;
Ansari, M. Azim ;
Bara, Anna ;
Bittaye, Mustapha ;
Broadhead, Samantha ;
Brown, Anthony ;
Brown, Helen ;
Cappuccini, Federica ;
Cooney, Enya ;
Dejnirattisai, Wanwisa ;
Dold, Christina ;
Fairhead, Cassandra ;
Fok, Henry ;
Folegatti, Pedro M. ;
Fowler, Jamie ;
Gibbs, Charlotte ;
Goodman, Anna L. ;
Jenkin, Daniel ;
Jones, Mathew ;
Makinson, Rebecca ;
Marchevsky, Natalie G. ;
Mujadidi, Yama F. ;
Nguyen, Hanna ;
Parolini, Lucia ;
Petersen, Claire ;
Plested, Emma ;
Pollock, Katrina M. ;
Ramasamy, Maheshi N. ;
Rhead, Sarah ;
Robinson, Hannah ;
Robinson, Nicola ;
Rongkard, Patpong ;
Ryan, Fiona ;
Serrano, Sonia ;
Tipoe, Timothy ;
Voysey, Merryn ;
Waters, Anele ;
Zacharopoulou, Panagiota ;
Barnes, Eleanor ;
Dunachie, Susanna ;
Goulder, Philip ;
Klenerman, Paul .
LANCET HIV, 2021, 8 (08) :E474-E485
[7]   Impaired antibody response to COVID-19 vaccination in advanced HIV infection [J].
Hassold, Nolan ;
Brichler, Segolene ;
Ouedraogo, Elise ;
Leclerc, Delphine ;
Carroue, Sophie ;
Gater, Yamina ;
Alloui, Chakib ;
Carbonnelle, Etienne ;
Bouchaud, Olivier ;
Mechai, Frederic ;
Cordel, Hugues ;
Delagreverie, Heloise .
AIDS, 2022, 36 (04) :F1-F5
[8]   Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China [J].
Huang, Xiaojie ;
Yan, Ying ;
Su, Bin ;
Xiao, Dong ;
Yu, Maohe ;
Jin, Xia ;
Duan, Junyi ;
Zhang, Xiangjun ;
Zheng, Shimin ;
Fang, Yuan ;
Zhang, Tong ;
Tang, Weiming ;
Wang, Lunan ;
Wang, Zixin ;
Xu, Junjie .
VIRUSES-BASEL, 2022, 14 (02)
[9]   Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1 [J].
Levy, Itzchak ;
Wieder-Finesod, Anat ;
Litchevsky, Vladyslav ;
Biber, Asaf ;
Indenbaum, Victoria ;
Olmer, Liraz ;
Huppert, Amit ;
Mor, Orna ;
Goldstein, May ;
Levin, Einav Gal ;
Hod, Tammy ;
Cohen, Carmit ;
Lustig, Yaniv ;
Rahav, Galia .
CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (12) :1851-1855
[10]  
Liu YB, 2021, BMC INFECT DIS, V21, DOI [10.1186/s12889-021-11927-x, 10.1186/s12879-021-06723-2, 10.1186/s12870-021-03229-6, 10.1186/s12905-021-01493-0]